Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05187884
Title Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM)
Acronym NADOM
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Anthony Joshua, FRACP
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.